• Alina Daniela BELCEANU “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
  • Stefana Catalina BILHA “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
  • Cristina PREDA “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania


To promote linear growth, it is essential to have normal phosphate homeostasis. Growth hormone/insulin-like growth factor (GH/IGF1) axis is a major regulator of phosphate metabolism and children with growth hormone deficiency (GHD) have increased renal phosphorus reabsorption during rhGH therapy. The novel phosphaturic fibroblast growth factor 23 (FGF23) has opposing effects, but the underlying mechanisms and interplay between both systems remain unclear. Aim: The main objective of this study is to investigate the possible interactions of FGF23 with the GH/IGF1 axis in the regulation of growth, calcium-phosphorus metabolism, and bone mineral density (BMD) in GHD children during the first year of treatment. Material and methods: Prospective, observational study of 42 non-obese prepubertal GHD children of both sexes, investigating changes in plasma FGF23, markers of mineral metabolism, and IGF-1 in the first year of rhGH therapy. Results: All children grew at an accelerated pace. Total BMD and total bone mineral content significantly increased after 12 months. The increase in serum phosphate was accompanied by a significant increase in plasma cFGF23 and IGF1. We found a positive association between SDS Height with IGF1 and FGF23 levels. No impact of FGF23 concentration variations on BMD was determined. Conclusions: FGF23 rises during rhGH therapy, an unanticipated observation given the role of FGF23 as a phosphaturic factor. GHD children have increased phosphate, associated with upregulation rather than with suppression of the phosphaturic FGF23. The association of FGF23 with height and IGF1 could indicate complex interactions between both axes in promoting linear growth.

Author Biographies

Alina Daniela BELCEANU, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

Faculty of Medicine
Department of Medical Specialties (II)

Stefana Catalina BILHA, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

Faculty of Medicine
Department of Medical Specialties (II)

Cristina PREDA, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

Faculty of Medicine
Department of Medical Specialties (II)


1. Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 2014; 66: 8-14.
2. Efthymiadou A, Kritikou D, Mantagos S, Chrysis D. The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children. Eur J Endocrinol 2016; 174(4): 473-479.
3. Bex M, Bouillon R. Growth hormone and bone health. Horm Res 2003; 60(Suppl 3): 80-86.
4. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998; 19(1): 55-79.
5. Balercia G, Giovannini L, Paggi F, et al. Growth hormone deficiency in the transition period: body composition and gonad function. J Endocrinol Invest 2011; 34(9): 709-715.
6. Kužma M, Killinger Z, Jackuliak P, et al. Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. Physiol Res 2019; 30; 68(Suppl 2): S121-S129.
7. Krabbe S, Transbøl I, Christiansen C. Bone mineral homeostasis, bone growth, and mineralization during years of pubertal growth: a unifying concept. Arch Dis Child 1982; 57(5): 359-363.
8. Gardner J, Ashraf A, You Z, McCormick K. Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy. J Pediatr Endocrinol Metab 2011; 24(9-10): 645-650.
9. Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 2014; 35(2): 234-281.
10. Nishiyama S, Ikuta M, Nakamura T, Tomoeda S, Matsuda I. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children. J Clin Endocrinol Metab 1992; 74(4): 906-909.
11. Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S, Fujita T. Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr J 2007; 54(3): 481-484.
12. Bilha SC, Bilha A, Ungureanu MC, et al. FGF23 Beyond the Kidney: A New Bone Mass Regulator in the General Population. Horm Metab Res 2020; 52(5): 298-304.
13. Wang Y, Wang H, Chen P. Higher Fibroblast Growth Factor 23 Levels Are Causally Associated With Lower Bone Mineral Density of Heel and Femoral Neck: Evidence From Two-Sample Mendelian Randomization Analysis. Front Public Health 2020; 8: 467.
14. Mirza MA, Karlsson MK, Mellström D, et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Mineral Res 2011; 26: 857-864.
15. Romanian National Therapeutic Protocol for the diagnosis and treatment of growth hormone deficiency children, 2018.
16. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993; 122: 37-45.
17. Martin A, David V, Quarles LD. Regulation and function of the FGF23/Klotho endocrine pathways. Physiol Rev 2012; 92(1): 131-155.
18. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10): 6120-6123.
19. Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 2009; 299: 72-78.
20. Siahanidou T, Garatzioti M, Lazaropoulou C, et al. Plasma soluble alpha-klotho protein levels in premature and term neonates: correlations with growth and metabolic parameters. Eur J Endocrinol 2012; 167(3): 433-440.
21. Capozzi A, Casa SD, Altieri B, Pontecorvi A. Low bone mineral density in a growth hormone deficient (GHD) adolescent. Clin Cases Miner Bone Metab 2013; 10(3): 203-235.
22. El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gatroenterol 2012; 12: 44.
23. Carrillo-López N, Panizo S, Alonso-Montes C et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 2016; 90: 77-89.
24. Wolf I, Shahmoon S, Ben Ami M, et al. Association between decreased klotho blood levels and organic growth hormone deficiency in children with growth impairment. PLoS ONE 2019: e107174.
25. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113(4): 561-568 / doi: 10.1172/JCI19081.
26. Kuro OM. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013; 9(11): 650-660.
27. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinol 2004; 145(7): 3087-3094.
28. Zheng S, Chen Y, Zheng Y, Zhou Z, Li Z. Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients. Eur J Med Res 2018; 23(1): 18.
29. Coskun Y, Paydas S, Balal M, Soyupak S, Kara E. Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients. Transplant Proc 2016; 48(6): 2040-2045.
30. Jovanovich A, Bùzková P, Chonchol M, et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. J Clin Endocrinol Metab 2013; 98(8): 3323-3331.